Leerink Partnrs Expects Increased Earnings for Equillium

Equillium, Inc. (NASDAQ:EQ) – Equities research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Equillium in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.83) per share for the year, up from their previous forecast of ($1.50). The consensus estimate for Equillium’s current full-year earnings is ($0.02) per share.

Equillium Trading Up 15.5 %

Shares of NASDAQ:EQ opened at $0.89 on Monday. The firm has a market capitalization of $31.50 million, a PE ratio of -6.35 and a beta of 1.79. Equillium has a 1-year low of $0.49 and a 1-year high of $3.25. The business’s 50 day moving average is $0.70 and its 200-day moving average is $0.81.

Hedge Funds Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC increased its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,400 shares of the company’s stock after buying an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned 0.85% of Equillium worth $208,000 at the end of the most recent reporting period. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.